

-Remarks-

Restriction requirement.

The Examiner has required restriction of the claims of the instant application to one of three groups:

Group I: Claims 1 - 26 and 43 - 47, drawn to 2-alkylurea adenosine derivatives, pharmaceutical compositions, processes for their preparation, and the intermediates used in those processes.

Group II: Claims 27 - 42, drawn to methods to treat various diseases using said 2-alkylurea adenosine derivatives.

Group III: Claim 47, drawn to adenine derivatives.

Applicants hereby elect Group I, without traverse.

The Examiner has further required that, if Group I is elected, Applicants elect a single disclosed species within the scope of Group I. Applicants hereby elect the compound of Example 1. That compound, named N-({9-[(2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9*H*-purin-2-yl)methyl)-N'-[2-(diisopropylamino)ethyl]urea, is the compound of formula (I) of claim 1 wherein R¹ is 2,3-diphenylethyl; R² and R³ are each H; R⁴ is N,N-diisopropylaminoethyl; R⁵ is hydroxymethyl; X is -CH₂- and Y is carbonyl. The elected species reads on claims 1 - 18 and 23 - 26.

Amendments:

Entry of the above amendments is respectfully requested. Claims 43 - 46 were amended to clarify the language. In claims 44 and 45, e.g., the claims recited "preferred" elements. Such language was deleted. Claims 27 - 43 and 47 were canceled to conform the claims to the group elected in response to the restriction requirement. All amendments and cancelations were made without waiver or prejudice. Applicants reserve the right to file divisional or continuation applications directed to the nonelected or other subject matter of this invention not within the scope of the current claims.

New claims 48 through 54 were added to claim subject matter that was "preferred" in claims 44 and 45.

Applicants have added seven new dependent claims and have canceled seventeen claims. Accordingly, Applicants submit that no fee is required for the addition of claims 48 - 54.

-Conclusion-

Applicants, having responded to all points and concerns raised by the Examiner, believe this application to be in condition for allowance. An early and favorable action is respectfully requested.

Dated: March 25, 2003

Respectfully submitted,

Robert T. Ronau

Robert T. Ronau

Attorney for Applicants

Reg. No. 36,257

Pfizer Inc.
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 441-5910